Top

Published in:

25-01-2024 | NSCLC | Thoracic Oncology

Multimodality Management of Thoracic Tumors: Initial Experience With a Multidisciplinary Thoracic Ablation Conference

Authors: Alexander Graur, cand. med., Jonathan A. Saenger, MD, Nathaniel D. Mercaldo, PhD, Judit Simon, MD, PhD, Eric D. Abston, MD, Melissa C. Price, MD, Kori Lanciotti, PA-C, Lauren A. Swisher, PA-C, Yolonda L. Colson, MD, PhD, Henning Willers, MD, Michael Lanuti, MD, Florian J. Fintelmann, MD

Published in: Annals of Surgical Oncology | Issue 5/2024

Abstract

Background

This study aimed to describe lesion-specific management of thoracic tumors referred for consideration of image-guided thermal ablation (IGTA) at a newly established multidisciplinary ablation conference.

Methods

This retrospective single-center cohort study included consecutive patients with non-small cell lung cancer (NSCLC) or thoracic metastases evaluated from June 2020 to January 2022 in a multidisciplinary conference. Outcomes included the management recommendation, treatments received (IGTA, surgical resection, stereotactic body radiation therapy [SBRT], multimodality management), and number of tumors treated per patient. Pearson’s chi-square test was used to assess for a change in management, and Poisson regression was used to compare the number of tumors by treatment received.

Results

The study included 172 patients (58 % female; median age, 69 years; 56 % thoracic metastases; 27 % multifocal primary lung cancer; 59 % ECOG 0 [range, 0–3]) assessed in 206 evaluations. For the patients with NSCLC, IGTA was considered the most appropriate local therapy in 12 %, equal to SBRT in 22 %, and equal to lung resection in 3 % of evaluations. For the patients with thoracic metastases, IGTA was considered the most appropriate local therapy in 22 %, equal to SBRT in 12 %, and equal to lung resection in 3 % of evaluations. Although all patients were referred for consideration of IGTA, less than one third of patients with NSCLC or thoracic metastases underwent IGTA (p < 0.001). Multimodality management allowed for treatment of more tumors per patient than single-modality management (p < 0.01).

Conclusions

Multidisciplinary evaluation of patients with thoracic tumors referred for consideration of IGTA significantly changed patient management and facilitated lesion-specific multimodality management.

Available only for authorised users

Howington JA, Blum MG, Chang AC, Balekian AA, Murthy SC. Treatment of stages I and II non-small cell lung cancer: diagnosis and management of lung cancer. 3rd ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2013;143(5 Suppl):e278S–e313S. https://doi.org/10.1378/chest.12-2359.

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Non-small cell lung cancer. Published online 17 February 2023. Retrieved 5 April 2023 at https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Colon cancer. Published online 29 March 2023. Retrieved 5 April 2023 at https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf.

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Soft tissue sarcoma. Published online 13 March 2023. Retrieved 5 April 2023 at https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf.

Altorki N, Wang X, Kozono D, et al. Lobar or sublobar resection for peripheral stage IA non-small cell lung cancer. N Engl J Med. 2023;388:489–98. https://doi.org/10.1056/NEJMoa2212083.CrossRefPubMedPubMedCentral

Donington J, Ferguson M, Mazzone P, et al. American college of chest physicians and society of thoracic surgeons consensus statement for evaluation and management for high-risk patients with stage I non-small cell lung cancer. Chest. 2012;142:1620–35. https://doi.org/10.1378/chest.12-0790.CrossRefPubMed

Gomez DR, Li H, Chang JY. Proton therapy for early-stage non-small cell lung cancer (NSCLC). Transl Lung Cancer Res. 2018;7(2):199–204. https://doi.org/10.21037/tlcr.2018.04.12.CrossRefPubMedPubMedCentral

Murphy MC, Wrobel MM, Fisher DA, Cahalane AM, Fintelmann FJ. Update on image-guided thermal lung ablation: society guidelines, therapeutic alternatives, and postablation imaging findings. AJR Am J Roentgenol. 2022;219:471–85. https://doi.org/10.2214/AJR.21.27099.CrossRefPubMed

Detterbeck FC, Blasberg JD, Woodard GA, et al. A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation—part 1: a guide to decision-making. J Thorac Dis. 2022;14(6):2340–2356. https://doi.org/10.21037/jtd-21-1823.CrossRefPubMedPubMedCentral

10.

Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol Off J Eur Soc Med Oncol. 2016;27:1386–422. https://doi.org/10.1093/annonc/mdw235.CrossRef

11.

Osarogiagbon RU. Making the evidentiary case for universal multidisciplinary thoracic oncologic care. Clin Lung Cancer. 2018;19:294–300. https://doi.org/10.1016/j.cllc.2018.05.006.CrossRefPubMed

12.

American Society of Clinical Oncology, European Society for Medical Oncology. ASCO-ESMO consensus statement on quality cancer care. Ann Oncol Off J Eur Soc Med Oncol. 2006;17:1063–4. https://doi.org/10.1093/annonc/mdl152.

13.

von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61:344–9. https://doi.org/10.1016/j.jclinepi.2007.11.008.CrossRef

14.

Tzartzas K, Oberhauser PN, Marion-Veyron R, Bourquin C, Senn N, Stiefel F. General practitioners referring patients to specialists in tertiary healthcare: a qualitative study. BMC Fam Pract. 2019;20:165. https://doi.org/10.1186/s12875-019-1053-1.CrossRefPubMedPubMedCentral

15.

Leppelmann KS, Fintelmann FJ. ASO Author Reflections: percutaneous image-guided ablation and multi-modality management of lung metastases. Ann Surg Oncol. 2021;28:5840–1. https://doi.org/10.1245/s10434-021-09784-4.CrossRefPubMed

16.

Jones CM, Brunelli A, Callister ME, Franks KN. Multimodality treatment of advanced non-small cell lung cancer: where are we with the evidence? Curr Surg Rep. 2018;6:5. https://doi.org/10.1007/s40137-018-0202-0.CrossRefPubMedPubMedCentral

17.

Gomez DR, Blumenschein GR, Lee JJ, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomized, controlled, phase 2 study. Lancet Oncol. 2016;17:1672–82. https://doi.org/10.1016/S1470-2045(16)30532-0.CrossRefPubMedPubMedCentral

18.

Bott MJ, Patel AP, Crabtree TD, et al. Role for surgical resection in the multidisciplinary treatment of stage IIIB non-small cell lung cancer. Ann Thorac Surg. 2015;99:1921–8. https://doi.org/10.1016/j.athoracsur.2015.02.033.CrossRefPubMedPubMedCentral

19.

Riedel RF, Wang X, McCormack M, et al. Impact of a multidisciplinary thoracic oncology clinic on the timeliness of care. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2006;1:692–6.

20.

Conron M, Phuah S, Steinfort D, Dabscheck E, Wright G, Hart D. Analysis of multidisciplinary lung cancer practice. Intern Med J. 2007;37:18–25. https://doi.org/10.1111/j.1445-5994.2006.01237.x.CrossRefPubMed

21.

Stevenson MM, Irwin T, Lowry T, et al. Development of a virtual multidisciplinary lung cancer tumor board in a community setting. J Oncol Pract. 2013;9:e77-80. https://doi.org/10.1200/JOP.2013.000882.CrossRefPubMedPubMedCentral

22.

Munden RF, Swisher SS, Stevens CW, Stewart DJ. Imaging of the patient with non–small cell lung cancer. Radiology. 2005;237:803–18. https://doi.org/10.1148/radiol.2373040966.CrossRefPubMed

23.

Dupuy DE, Fernando HC, Hillman S, et al. Radiofrequency ablation of stage IA non-small cell lung cancer in medically inoperable patients: results from the American College of Surgeons Oncology Group Z4033 (Alliance) trial. Cancer. 2015;121:3491–8. https://doi.org/10.1002/cncr.29507.CrossRefPubMed

24.

Pennathur A, Brunelli A, Criner GJ, et al. Definition and assessment of high risk in patients considered for lobectomy for stage I non-small cell lung cancer: the American Association for Thoracic Surgery expert panel consensus document. J Thorac Cardiovasc Surg. 2021;162:1605-18.e6. https://doi.org/10.1016/j.jtcvs.2021.07.030.CrossRefPubMed

25.

Bourgouin PP, Wrobel MM, Mercaldo ND, et al. Comparison of percutaneous image-guided microwave ablation and cryoablation for sarcoma lung metastases: a 10-year experience. AJR Am J Roentgenol. 2022;218:494–504. https://doi.org/10.2214/AJR.21.26551.CrossRefPubMed

26.

Juan O, Popat S. Ablative therapy for oligometastatic non-small cell lung cancer. Clin Lung Cancer. 2017;18:595–606. https://doi.org/10.1016/j.cllc.2017.03.002.CrossRefPubMed

27.

Ahmed KA, Scott JG, Arrington JA, et al. Radiosensitivity of lung metastases by primary histology and implications for stereotactic body radiation therapy using the genomically adjusted radiation dose. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2018;13:1121–7. https://doi.org/10.1016/j.jtho.2018.04.027.CrossRef

28.

Sänger JA, Graur A, Tahir I, et al. Outcomes following cryoablation of stage IA non-small cell lung cancer in patients with and without interstitial lung disease: a retrospective single-center cohort study. Lung Cancer. 2023;181:107231. https://doi.org/10.1016/j.lungcan.2023.107231.CrossRefPubMed

29.

Brooks ED, Verma V, Senan S, et al. Salvage therapy for locoregional recurrence after stereotactic ablative radiotherapy for early-stage NSCLC. J Thorac Oncol. 2020;15:176–89. https://doi.org/10.1016/j.jtho.2019.10.016.CrossRefPubMed

30.

Genshaft SJ, Suh RD, Abtin F, et al. Society of Interventional Radiology Quality Improvement standards on percutaneous ablation of non-small cell lung cancer and metastatic disease to the lungs. JVIR J Vasc Interv Radiol. 2021;32:1242.e1-1242.e10. https://doi.org/10.1016/j.jvir.2021.04.027.CrossRefPubMed

Title: Multimodality Management of Thoracic Tumors: Initial Experience With a Multidisciplinary Thoracic Ablation Conference
Authors: Alexander Graur, cand. med.
Jonathan A. Saenger, MD
Nathaniel D. Mercaldo, PhD
Judit Simon, MD, PhD
Eric D. Abston, MD
Melissa C. Price, MD
Kori Lanciotti, PA-C
Lauren A. Swisher, PA-C
Yolonda L. Colson, MD, PhD
Henning Willers, MD
Michael Lanuti, MD
Florian J. Fintelmann, MD
Publication date: 25-01-2024
Publisher: Springer International Publishing
Keywords: NSCLC
NSCLC
Thoracic Cancer
Thoracic Tumor
Metastasis
Published in: Annals of Surgical Oncology / Issue 5/2024
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-024-14910-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Multimodality Management of Thoracic Tumors: Initial Experience With a Multidisciplinary Thoracic Ablation Conference

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2024

ASO Visual Abstract: Variation in Hospital Mortality After Complex Cancer Surgery—Patient, Volume, Hospital, or Social Determinants?

Clinical Impact of Conversion Surgery After Induction Therapy for Esophageal Cancer with Synchronous Distant Metastasis: A Multi-institutional Retrospective Study

ASO Visual Abstract: Determination of Factors Associated with Upstage in Atypical Ductal Hyperplasia to Identify Low-Risk Patients Where Active Surveillance May be an Alternative

Expanding the Use of HIPEC in Ovarian Cancer at Time of Interval Debulking Surgery to FIGO Stage IV and After 6 Cycles of Neoadjuvant Chemotherapy: A Prospective Analysis on Perioperative and Oncologic Outcomes

ASO Visual Abstract: Association of COVID-19 Pandemic with Colorectal Cancer Screening: Impact of Race/Ethnicity and Social Vulnerability

Race Affects Patients’ Likelihood of Being Offered Surgical Resection for Small Bowel Neuroendocrine Neoplasms